Mesenchymal stem cell (MSC) transplantation is regarded as a promising candidate for the
treatment of ischaemic heart disease. The major hurdles for successful clinical translation of …

BACKGROUND: Bone marrow mesenchymal stem cells (MSCs) can be used for myocardial
repair following myocardial infarction. Increased expression of stromal cell-derived factor-1 …

Bone marrow mesenchymal stem cells (MSCs) are considered as a promising cell source to
treat the acute myocardial infarction. However, over 90% of the stem cells usually die in the …

Background Heart failure due to ischemic heart disease is still a major health problem.
Myocardium regeneration emerges as a novel therapeutic method for treating myocardial …

Myocardial infarction is associated with persistent muscle damage, scar formation and
depressed cardiac performance. Recent studies have demonstrated the clinical significance …

Stem cell transplantation at the time of acute myocardial infarction (AMI) improves cardiac
function. Whether the improved cardiac function results from regeneration of cardiac …

Stem cell therapy has shown promise in treating a variety of pathologies, such as myocardial
infarction, ischaemic stroke and organ transplantation. The stromal cell-derived factor-1 …

Background Human mesenchymal stem cells (MSC) have been utilized for cardiac
regeneration after myocardial damage. Their clinical effects are marginal and only a minority …

Mesenchymal stem cell (MSC) therapy for the treatment of myocardial infarction (MI) has
shown considerable promise in clinical trials. A billion MSCs need to be administered for …

Abstract Stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, are crucial for
homing and migration of multiple stem cell types. Their potential role in mediating bone …